A groundbreaking study published in the per reviewed journal Neurotherapeutics shows that a combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) may offer new hope for treating Alzheimer’s disease (AD).
“A combination of Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) at non-psychoactive doses was previously demonstrated to reduce cognitive decline in APP/PS1 mice, an animal model of Alzheimer’s disease (AD)”, starts the study’s abstract. “However, the neurobiological substrates underlying these therapeutic properties of Δ9-THC and CBD are not fully understood.”
Considering that dysregulation of glutamatergic activity contributes to cognitive impairment in AD, the present study “evaluates the hypothesis that the combination of these two natural cannabinoids might reverse the alterations in glutamate dynamics within the hippocampus of this animal model of AD.”
Continue reading